In the context of bladder cancer, dysregulation or reduced expression of the SWI/SNF complex and its specific subunits such as ARID1A [60] and SNF5 [58] is closely linked to tumour progression, offering a novel therapeutic target. Here, ARID1A is linked to urinary bladder cancer.